Health & Fitness
Thu, March 3, 2011Wed, March 2, 2011Tue, March 1, 2011Mon, February 28, 2011Sun, February 27, 2011Fri, February 25, 2011Thu, February 24, 2011Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Obagi Medical Products to Report Fourth Quarter and Year End 2010 Financial Results and Host a Conference Call on March 10th
//health-fitness.news-articles.net/content/2011/ .. ts-and-host-a-conference-call-on-march-10th.html
Published in Health and Fitness on Wednesday, February 23rd 2011 at 13:11 GMT by Market WireLONG BEACH, Calif.--([ BUSINESS WIRE ])--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that it will report financial results for its fourth quarter and fiscal year ended December 31, 2010 on March 10, after market close, followed by an investor conference call on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Investors interested in participating in the live call can dial 877-407-0784 from the U.S. International callers can dial 201-689-8560. A telephone replay will be available approximately two hours after the call concludes through Thursday, March 24, 2011, by dialing 877-870-5176 from the U.S., or 858-384-5517 for international callers, and entering replay pin # 367169.
There also will be a simultaneous webcast available on the Investor Relations section of the Company's web site at [ www.obagi.com ]. For those unable to participate during the live broadcast, the webcast will be archived for 30 days.
About Obagi Medical Products, Inc.
Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeuticsa" technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition & Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm D©colletage System, Obagi Rosaclear® System, Obagi ELASTILasha" Eyelash Solution, Obagi Blue Peel RADIANCEa", and Nu-Derm® Sun Shield SPF 50. Visit [ www.obagi.com ] for more information.
